Assessing personalized medicines in Australia: A national framework for reviewing codependent technologies

Medical Decision Making

Volumn 33, Issue 3, 2013, Pages 333-342

  Merlin, Tracy ^a   Farah, Claude ^a   Schubert, Camille ^a   Mitchell, Andrew ^b   Hiller, Janet E ^c   Ryan, Philip ^d  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b Canberra ACT   (Australia)

^c AUSTRALIAN CATHOLIC UNIVERSITY   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

drug approval process; genetic testing; personalized medicine; reimbursement mechanisms

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; AUSTRALIA; PERSONALIZED MEDICINE;

AUSTRALIA; BIOLOGICAL MARKERS; INDIVIDUALIZED MEDICINE;

EID: 84871438780     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X12452341     Document Type: Article

References (37)

1. Finkelstein Y, Bournissen FG, Hutson JR, Shannon M. Polymorphism of the ADRB2 gene and response to inhaled beta- agonists in children with asthma: a meta-analysis. J Asthma. 2009 ; 46 (9). 900-5
2. Roden DM, Altman RB, Benowitz MD, et al. Pharmacogenomics: challenges and opportunities. Ann Intern Med. 2006 ; 145: 749-57
3. Wang B, Wang J, Huang SQ, Su HH, Zhou SF. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. Curr Drug Metab. 2009 ; 10 (7). 781-834
4. Xie H-G, Frueh FW. Pharmacogenomics steps toward personalized medicine. Future Med. 2005 ; 2 (4). 325-37
5. Food and Drug Administration, Department of Health and Human Services. Drug-diagnostic co-development: concept paper. 2005.
6. Scartozzi M, Bearzi I, Mandolesi A, et al. Epidermal growth factor receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. BMC Cancer. 2009 ; 9: 303
7. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008 ; 359 (17). 1757-65
8. Lurje G, Lenz HJ. EGFR signaling and drug discovery. Oncology. 2009 ; 77 (6). 400-10
9. Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol. 1999 ; 26: 71-7
10. Tamura K, Okamoto I, Kashii T, et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer. 2008 ; 98 (5). 907-14
11. Essers BA, Seferina SC, Tjan-Heijnen VC, et al. Transferability of model-based economic evaluations: the case of trastuzumab for the adjuvant treatment of HER2-positive early breast cancer in the Netherlands. Value Health. 2010 ; 13 (4). 375-80
12. Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics. 2010 ; 28 (1). 61-74
13. Wong W, Carlson J, Thariani R, Veenstra D. Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics. 2010 ; 28 (11). 1001-13
14. Conti R, Veenstra DL, Armstrong K, Lesko LJ, Grosse SD. Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Med Decis Making. 2010 ; 30 (3). 328-40
15. Personalised medicine. Postnote. 2009 ;: 329
16. Terasawa T, Dahabreh I, Castaldi P, Trikalinos T Rockville, MD: Agency for Healthcare Research and Quality ; 2009 :
17. Laksman Z, Detsky AS. Personalized medicine: understanding probabilities and managing expectations. J Gen Intern Med. 2011 ; 26 (2). 204-6
18. Meckley LM, Neumann PJ. Personalized medicine: factors influencing reimbursement. Health Policy. 2010 ; 94 (2). 91-100
19. Schmitt F. HER2+ breast cancer: how to evaluate?. Adv Ther. 2009 ; 26: S1-8
20. Canberra, Australis: Commonwealth of Australia ; 2009 :
21. Buckley E, Merlin T Canberra, Australia: Australian Government ; 2010 :
22. Bradford Hill A. The environment and disease: association or causation?. Proceedings of the Royal Society of Medicine. 1965 ; 58: 295-300
23. Canberra, Australia: Commonwealth of Australia ; 2008 :
24. Rockville, MD: Food and Drug Administration ; 2005 :
25. US Department of Health and Human Services ;
26. Lee CK, Lord SJ, Coates AS, Simes RJ. Molecular biomarkers to individualise treatment: assessing the evidence. Med J Aust. 2009 ; 190 (11). 631-6
27. Clark GM, Zborowski DM, Culbertson JL, et al. Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib. J Thorac Oncol. 2006 ; 1: 837-46
28. Lord SJ, Irwig L, Bossuyt PM. Using the principles of randomized controlled trial design to guide test evaluation. Med Decis Making. 2009 ; 29 (5). E1 - E12
29. Merlin T, Weston A, Tooher R. Extending an evidence hierarchy to include topics other than treatment: revising the Australian "levels of evidence. " BMC Med Res Methodol. 2009 ; 9: 34
30. Rockville, MD: Agency for Healthcare Research and Quality, US Department of Health and Human Services ; 2010 :
31. Centers for Disease Control and Prevention, Office of Public Health Genomics. ACCE Model List of 44 Targeted Questions Aimed at a Comprehensive Review of Genetic Testing 2010 [cited]. Available from: URL: http://www.cdc.gov/genomics/gtesting/ACCE/acce-proj.htm
32. Rockville, MD: US Department of Health and Human Services ; 2011 :
33. London: National Institute of Health and Clinical Excellence Centre for Health Technology Evaluation, Diagnostics Assessment Programme ; 2010 :
34. European Network for Health Technology Assessment ; 2008 :
35. Canberra, Australia: Commonwealth of Australia ; 2005 :
36. Steinberg EP, Tunis S, Shapiro D. Insurance coverage for experimental technologies. Health Affairs. 1995 ; 14: 143-58
37. Garrison LP, Austin MJF. The economics of personalized medicine: a model of incentives for value creation and capture. Drug Information Journal. 2007 ; 41: 501-9